In recent years, the advent of checkpoint blockade immunotherapy has profoundly transformed the treatment paradigm for lung cancer, particularly through the utilization of monoclonal antibodies targeting programmed death-1/programmed death-ligand 1 (PD-1/PD-L1)2–5. This evidence concerns the gene CD274 and lung carcinoma.